Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.41 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | YAP1 | P46937 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599317 | 0.91 | CXCR2 (0.37) | CXCR2KIFC1FNTAFNTB | |
| SCHEMBL25599374 | 0.91 | CXCR2 (0.51) | CXCR2KIFC1PTPN1YAP1 | |
| SCHEMBL25599284 | 0.91 | CXCR2 (0.51) | CXCR2KIFC1PTPN1YAP1 | |
| SCHEMBL25599455 | 0.90 | PTPN1 (0.37) | CXCR2PTPN1 | |
| SCHEMBL25599046 | 0.89 | CXCR2 (0.41) | CXCR2PTPN1YAP1 | |
| SCHEMBL25599246 | 0.89 | CXCR2 (0.45) | CXCR2KIFC1CASP1CASP3CASP7 | |
| SCHEMBL25599341 | 0.88 | CXCR2 (0.40) | CXCR2KIFC1CASP1CASP3CASP7 | |
| SCHEMBL25599278 | 0.88 | CXCR2 (0.39) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599321 | 0.86 | CXCR2 (0.38) | CXCR2CASP1CASP3CASP7CASP6 | |
| SCHEMBL25599493 | 0.85 | CXCR2 (0.36) | CXCR2PTPN1FNTAFNTBYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885KIFC1 4789/4885LMNA 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.